Breaking News, Collaborations & Alliances

Cyclolab and EpiPharma Form Joint Venture

Will develop and commercialize Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.

By: Contract Pharma

Contract Pharma Staff

Cyclolab, a cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development company, have signed an agreement to form a joint venture specialty pharmaceutical company to develop and commercialize novel conjugated Cyclodextrin – Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.   According to the agreement, the new joint venture will be named Targetrin Therapeutics LLC (Targetrin). Both fou...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters